Blog

[:content [\N \I \C \E \space \h \a \s \  \r \e \c \o \m \m \e \n \d \e \d \  \e \l \t \r \o \m \b \o \p \a \g \space \o \l \a \m \i \n \e \  \( \R \e \v \o \l \a \d \e \, \space \G \S \K \) \space \a \s \space \a \n \space \o \p \t \i \o \n \space \f \o \r \space \t \r \e \a \t \i \n \g \space \s \o \m \e \space \a \d \u \l \t \s \space \w \i \t \h \space \t \h \e \space \b \l \e \e \d \i \n \g \space \d \i \s \o \r \d \e \r \space \c \h \r \o \n \i \c \space \i \m \m \u \n \e \space \( \i \d \i \o \p \a \t \h \i \c \) \space \t \h \r \o \m \b \o \c \y \t \o \p \e \n \i \c \space \p \u \r \p \u \r \a \  \i \n " ..."]]

Drug companies are scrapping free access to breakthrough cancer treatments as the time ­between product registration and full approval blows ...

[:content [\5 \space \M \a \y \space \2 \0 \1 \4 \space \- \  \D \e \c \a \d \e \s \space \o \f \space \i \n \v \e \s \t \m \e \n \t \space \i \n \space \c \a \n \c \e \r \space \r \e \s \e \a \r \c \h \space \a \r \e \space \b \e \g \i \n \n \i \n \g \space \t \o \space \h \a \v \e \space \r \e \a \l \space \i \m \p \a \c \t \. \space \N \o \w \space \m \o \r \e \space \t \h \a \n \space \6 \0 \space \p \e \r " ..."]]

Medicines Australia CEO Tim James has welcomed the Department of Health’s confirmation that PBS growth was negligible for the 2013-14 ...

A stakeholder meeting was held on 24 June 2014 to discuss the PBS listing of eculizumab (Soliris) for atypical haemolytic uraemic ...

[:content [\A \space \b \a \s \i \c \space \p \r \e \d \i \c \t \i \o \n \space \o \f \space \t \h \e \o \r \e \t \i \c \a \l \space \m \o \d \e \l \s \space \o \f \space \i \n \s \u \r \a \n \c \e \space \i \s \space \t \h \a \t \space \i \f \space \c \o \n \s \u \m \e \r \s \space \h \a \v \e \space \p \r \i \v \a \t \e \space \i \n \f \o \r \m \a \t \i \o \n \space \a \b \o \u \t \space \t \h \e \i \r \space \r \i \s \k \space \o \f \space \s \u \f \f \e \r \i \n \g " ..."]]

The draft Report for Stage 3 of the Post-Market Review of Products used in the Management of Diabetes, focusing on ...

The links to the Public Summary Documents (PSDs) from the March 2014 PBAC meeting have been added to MAESTrO Australia PBAC. ...

The government will bank $3.7 billion in savings from its reforms to the Pharmaceutical Benefits Scheme, arguing that the drive ...

[:content [\1 \space \M \a \y \space \2 \0 \1 \4 \space \- \space \T \h \e \space \f \o \l \l \o \w \i \n \g \space \a \d \d \i \t \i \o \n \s \space \a \n \d \space \c \h \a \n \g \e \s \space \h \a \v \e \space \b \e \e \n \space \a \d \d \e \d \space \t \o \space \M \A \E \S \T \r \O \space \A \u \s \t \r \a \l \i \a \: " ..."]]

The Pharmaceutical Benefits Advisory Committee (PBAC) has released a statement on the safety of biosimilar medicines. ...

Indicative 1 October 2015 prices resulting from the 2015 October Cycle of Price Disclosure have now been published on the Price ...

A poll conducted as part of a campaign to improve access to cancer drugs has found more support for subsidised ...